接种阿斯利康 COVID-19 疫苗后的疫苗相关血栓形成的诊断和管理：GTH 的指导意见声明。
Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.
机构信息
Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
Vivantes Klinikum im Friedrichshain, Klinik für Innere Medizin Angiologie und Hämostaseologie, Berlin, Germany.
出版信息
Hamostaseologie. 2021 Jun;41(3):184-189. doi: 10.1055/a-1469-7481. Epub 2021 Apr 1.
The COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication. It shares pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
COVID-19 大流行是一场持续的全球医疗保健危机。基于接种阿斯利康 COVID-19 疫苗后出现异常位置血栓的报告，血栓与止血学会（GTH）发布了关于识别、诊断和治疗这种罕见并发症的指南声明。它与肝素诱导的血小板减少症（HIT）具有相同的病理生理学特征，被称为疫苗诱导的促血栓形成免疫性血小板减少症（VIPIT）。
Zotero 插件